Connection
David Raben to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications David Raben has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.080 |
|
|
|
-
Raben D, Bianco C, Helfrich B, Weng E, Ciardiello F, Harari P. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment. Expert Rev Anticancer Ther. 2002 Aug; 2(4):461-71.
Score: 0.049
-
Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2016 Apr 20; 34(12):1300-8.
Score: 0.031